<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/C7BC78" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method GTA-2: Hep G2 Hepatocarcinoma Cytotoxicity Assay</p><p><b>Protocol Abbreviation:</b> GTA-2</p><p><b>Protocol Version:</b> 1.4<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/C7BC78>http://dx.doi.org/10.17917/C7BC78</a></p><p><b>Protocol File:</b> protocols/20241210_19-22-19-573_NCL_Method_GTA-2.pdf<p><b>File Title:</b> GTA-2</p><p><b>Description:</b></b> This protocol describes the cytotoxicity testing of nanoparticle formulations in human hepatocarcinoma cells (Hep G2), as part of the in vitro NCL preclinical characterization cascade. The protocol utilizes two methods for estimation of cytotoxicity, 3-(4,5-Dimethyl-2-thiazolyl)2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction and lactate dehydrogenase (LDH) release.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>